Researchers at the University of Illinois at Chicago are the first to identify the presence of a specific type of antibody called anti-citrullinated protein autoantibodies or ACPAs in human tear fluid. They are also the first to demonstrate that patients with dry eye disease experienced reduced signs and symptoms of the condition in response to a new eye drop treatment -- made from human pooled antibodies -- that targets ACPAs. The findings from their early-stage clinical trial are reported in the journal -- The Ocular Surface. Dry eye disease is caused by abnormalities in the tear fluid and results in